Weatherden
Emma Tinsley currently serves as Chair and Chief Executive Officer at Remedy Rx since July 2021 and as Chief Executive Officer and Chief Financial Officer at Weatherden since November 2017. Additionally, Emma has been an advisor at Science Creates Ventures since June 2020. Previous experience includes roles as Investment Associate and Finance and Operations Manager at SV Health Investors from October 2015 to September 2018, as well as Assistant Manager in Accounting and Advisory Services at KPMG from October 2010 to September 2015. Emma began a career in administration at West Kent College from October 2009 to September 2010. Academic qualifications include an MSci in Chemistry from the University of Bristol and an ACA in Accounting from ICAEW.
This person is not in any teams
Weatherden
Weatherden is a global integrated clinical consultancy and experts in scientific strategy and clinical development that is trusted by biopharma, funds, startups, spin-outs and nonprofits. We advise companies from the earliest stages on scientific strategy, translational medicine and clinical development, through to diligence prep and support for M&A. Our focus is on de-risking programmes early, optimising clinical, regulatory, and commercial pathways from discovery to market and accelerating the translation of novel science into life-changing medicines for patients. Blending more than 900 years’ experience across the industry, we are invested in our clients’ success, motivated by the opportunity to rapidly improve the chances for breakthrough therapies to tackle unmet clinical need. Combining an agile biotech mindset with the proven expertise of pharmaceutical drug discovery and development, we work at the cutting edge of clinical, scientific and technological innovation to maximise value, enhance patient outcomes and simplify paths to market.